Benefits of GLP-1 Agonist

Main Article Content

Julian Ruben Alaniz
Juan Avila
Klarissa Renee Cantu
Joe Frank Cruz
Aileen Jaramillo
Hector De la Cruz
Fabiola Lopez Sanchez
Gia Pena
Alan Salinas
Sadie Faye Viera
Karely Cantu
Jacob Ryan Garcia

Keywords

metabolism, GLP-1, agonists

Abstract

there is no abstract. 

Abstract 183 | PDF Downloads 412

References

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. doi: 10.1152/physrev.00034.2006. PMID: 17928588.
2. Iorga RA, Bacalbasa N, Carsote M, et al. Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Exp Ther Med. 2020;20(3):2396-2400. doi:10.3892/etm.2020.8714
3. JPH;, B. E. H. D. (n.d.). SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications. Lancet (London, England). https://pubmed.ncbi.nlm.nih.gov/34216571
4. Professional Heart Daily. professional.heart.org.
5. Rm B, Pj F, Dm K. Racial Disparities in Cardiovascular Disease Risk: Mechanisms of Vascular Dysfunction. American journal of physiology. Heart and circulatory physiology. Published October 1, 2019. https://pubmed.ncbi.nlm.nih.gov/31397168/
6. What Is Ozempic®? | Ozempic® (semaglutide) Injection 0.5 mg or 1 mg. www.ozempic.com. https://www.ozempic.com/why-ozempic/what-is-ozempic.html
7. Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050-2068. Published 2021 May 11. doi:10.7150/ijbs.59965
8. Andrikou, E., Tsioufis, C., Andrikou, I., Leontsinis, I., Tousoulis, D., & Papanas, N. (2019). GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic Journal of Cardiology, 60(6), 347–351. https://doi.org/10.1016/j.hjc.2018.11.008
9. Brothers RM, Fadel PJ, Keller DM. Racial disparities in cardiovascular disease risk: mechanisms of vascular dysfunction. Am J Physiol Heart Circ Physiol. 2019 Oct 1;317(4):H777-H789. doi: 10.1152/ajpheart.00126.2019. Epub 2019 Aug 9. PMID: 31397168; PMCID: PMC6843015.
10. Zheng J, Xie Y, Ren L, et al. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease. Mol Metab. 2021;47:101180. doi:10.1016/j.molmet.2021.101180
11. Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022;179(4):625-641. doi:10.1111/bph.15677
12. Grill HJ. A Role for GLP-1 in Treating Hyperphagia and Obesity. Endocrinology. 2020;161(8):bqaa093. doi:10.1210/endocr/bqaa093
13. John Hopkins Medicine . Anatomy of the Endocrine System. Johns Hopkins Medicine. Published 2019. https://www.hopkinsmedicine.org/health/wellness-and-prevention/anatomy-of-the-endocrine-system
14. Soto-Tinoco E, Guerrero-Vargas NN, Buijs RM. Interaction between the hypothalamus and the immune system. Exp Physiol. 2016;101(12):1463-1471. doi:10.1113/EP085560
15. O'Shea D, Hogan AE. Dysregulation of Natural Killer Cells in Obesity. Cancers (Basel). 2019;11(4):573. Published 2019 Apr 23. doi:10.3390/cancers11040573
16. Conor De Barra, Khalil M, Mat A, et al. Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function. Published online May 9, 2023. https://doi.org/10.1002/oby.23772
17. Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27-36. doi:10.1016/j.jsbmb.2018.04.008
18. Ding H, Zhang J, Zhang F, et al. Resistance to the Insulin and Elevated Level of
Androgen: A Major Cause of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021;12:741764. Published 2021 Oct 20. doi:10.3389/fendo.2021.741764Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, Xie Q. Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021
19. Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25(4):504-517. doi:10.1093/humupd/dmz019
20. Thyroid: What It Is, Function & Problems. Cleveland Clinic. https://my.clevelandclinic.org/health/body/23188-thyroid#:~:text=It
21. CDC. What Is Type 1 Diabetes? Centers for Disease Control and Prevention. Published March 11, 2022. https://www.cdc.gov/diabetes/basics/what-is-type-1-diabetes.html.
22. Mayo Clinic. Type 2 Diabetes. Mayo Clinic. Published March 14, 2023. https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/symptoms-causes/syc-20351193.
23. Mayo Clinic. Cirrhosis - Symptoms and Causes. Mayo Clinic. Published February 6, 2021. https://www.mayoclinic.org/diseases-conditions/cirrhosis/symptoms-causes/syc-20351487
24. Liver: What It Does, Disorders & Symptoms, Staying Healthy. Cleveland Clinic. https://my.clevelandclinic.org/health/articles/21481-liver#:~:text=The%20liver%20filters%20(cleans)%20the
25. Diagnosis of NAFLD & NASH | NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/diagnosis
26. Morgan MY. The prognosis and outcome of alcoholic liver disease. Alcohol and Alcoholism (Oxford, Oxfordshire) Supplement. 1994;2:335-343. https://pubmed.ncbi.nlm.nih.gov/8974353/
27. Diagnosis of NAFLD & NASH | NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/diagnosis
28. Volpe S, Lisco G, Fanelli M, et al. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. 2022;14(21):4673-4673. doi:https://doi.org/10.3390/nu14214673
29. Tanday N, Flatt PR, Irwin N. Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands. British Journal of Pharmacology. Published online May 10, 2021. doi:https://doi.org/10.1111/bph.15485
30. Liver Functions, Location, Anatomy and Disease | Columbia Surgery. columbiasurgery.org. https://columbiasurgery.org/liver/liver-and-its-functions#:~:text=The%20Liver%20and%20Its%20Functions
31. Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiological Reviews. 2007;87(4):1409-1439. doi:https://doi.org/10.1152/physrev.00034.2006
32. Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021;12:721135. Published 2021 Aug 23. doi:10.3389/fendo.2021.721135
33. Kruepunga N, Hakvoort TBM, Hikspoors JPJM, Köhler SE, Lamers WH. Anatomy of rodent and human livers: What are the differences?. Biochim Biophys Acta Mol Basis Dis. 2019;1865(5):869-878. doi:10.1016/j.bbadis.2018.05.019
34. Takuya Funayama, Tsukasa Nozu, Masatomo Ishioh, et al. Centrally administered GLP-1 analogue improves intestinal barrier function through the brain orexin and the vagal pathway in rats. 2023;1809:148371-148371. doi:https://doi.org/10.1016/j.brainres.2023.148371
35. Okumura T, Nozu T, Ishioh M, et al. Oxytocin acts centrally in the brain to improve leaky gut through the vagus nerve and a cannabinoid signaling in rats. Physiology & Behavior. 2022;254:113914. doi:https://doi.org/10.1016/j.physbeh.2022.113914
36. Acuna-Goycolea C. Glucagon-Like Peptide 1 Excites Hypocretin/Orexin Neurons by Direct and Indirect Mechanisms: Implications for Viscera-Mediated Arousal.
Journal of Neuroscience. 2004;24(37):8141-8152. doi:https://doi.org/10.1523/jneurosci.1607-04.2004
37. Martin CR, Osadchiy V, Kalani A, Mayer EA. The Brain-Gut-Microbiome Axis. Cellular and Molecular Gastroenterology and Hepatology. 2018;6(2):133-148. doi:https://doi.org/10.1016/j.jcmgh.2018.04.003
38. Cleveland Clinic. Digestive system: Function, organs & anatomy. Cleveland Clinic. Published August 9, 2021. https://my.clevelandclinic.org/health/body/7041-digestive-system
39. Hunt JE, Holst JJ, Jeppesen PB, Kissow H. GLP-1 and Intestinal Diseases. Biomedicines. 2021;9(4):383. doi:https://doi.org/10.3390/biomedicines9040383

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>